Johan Rockberg

Professor at KTH Royal Institute of Technology

Speaker

Professor in directed evolution and antibody technology at KTH Royal Inst.Technology, Sweden. Director of GeneNova, a center focused on developing platforms for more cost effective, safe and efficacious AAV-based gene therapy through interdisciplinary industry and academia collaborations. He is an expert in protein and cell line engineering with 19000 citations and 55+ publications. Co-PI of human protein atlas program cataloging all human proteins. Co-founder of 5 companies including StrikePharma AB (Uppsala) developing cancer vaccine, Abclon (Seoul, South Korea) developing CAR-T and immunotherapy. Elected member of the Swedish Young Academy (SUA) and Royal Academy of Science (KVA) research policy committee.